Development of a new risk scoring system based on spleen involvement and the lymphocyte/monocyte ratio for follicular lymphoma patients

Abstract

BackgroundThis study aimed to retrospectively evaluate a large Chinese cohort's baseline characters and develop a new predictive scoring system. Methods: A total of 491 FL patients were reviewed, and 337newly diagnosed 1–3a FL patients from January 2010 to October 2020 were enrolled in our retrospective cohort. Results: Progression-free survival (PFS) was assessed as the first endpoint; the 2-year and 5-year PFS were 81.4% and 67.8%, respectively. A new risk scoring system (SLMR) was established after the univariable and multivariable analyses, and four independent factors such as β2-MG, LDH, LMR, the number of nodal areas ≥ 5, and spleen involvement were detected by FDG-PET imaging were included. The SLMR was compared with the existing models using discrimination and calibration, and k-fold cross-validation was performed for internal validation. Our cohort classified patients into three groups (low-, intermediate- and high) according to the SLMR and showed the best model performance, especially for FL3a and received rituximab maintenance after induction therapy patients.